Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study
KR Chapman, SI Rennard, A Dogra, R Owen… - Chest, 2011 - Elsevier
Background Indacaterol is an inhaled, long-acting β 2-agonist providing 24-h
bronchodilation with once-daily dosing in patients with COPD. Methods Subjects with …
bronchodilation with once-daily dosing in patients with COPD. Methods Subjects with …
[HTML][HTML] Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD
PW Jones, DA Mahler, R Gale, R Owen, B Kramer - Respiratory medicine, 2011 - Elsevier
BACKGROUND: Indacaterol is a novel, inhaled, ultra-long-acting β2-agonist bronchodilator
for maintenance use in patients with COPD. The aim of this paper is to assess the effect of …
for maintenance use in patients with COPD. The aim of this paper is to assess the effect of …
[HTML][HTML] Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
G Feldman, T Siler, N Prasad, D Jack, S Piggott… - BMC pulmonary …, 2010 - Springer
Background Indacaterol is a novel, once-daily (od) inhaled, long-acting β 2-agonist in
development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind …
development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind …
Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial
J Beier, P Chanez, JB Martinot, AJM Schreurs… - Pulmonary …, 2007 - Elsevier
In patients with chronic obstructive pulmonary disease (COPD) classified as moderate
onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines …
onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines …
Safety of indacaterol in the treatment of patients with COPD
JF Donohue, D Singh, O Kornmann… - … journal of chronic …, 2011 - Taylor & Francis
Purpose Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a
once-daily inhaled long-acting β2-agonist for chronic obstructive pulmonary disease …
once-daily inhaled long-acting β2-agonist for chronic obstructive pulmonary disease …
[HTML][HTML] Indacaterol once-daily is equally effective dosed in the evening or morning in COPD
H Magnussen, C Verkindre, D Jack, D Jadayel… - Respiratory …, 2010 - Elsevier
Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-h bronchodilation with
once-daily (od) dosing in patients with COPD. In this double-blind, incomplete block …
once-daily (od) dosing in patients with COPD. In this double-blind, incomplete block …
[HTML][HTML] Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
B Balint, H Watz, C Amos, R Owen… - … Journal of Chronic …, 2010 - ncbi.nlm.nih.gov
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
R Dahl, KF Chung, R Buhl, H Magnussen, V Nonikov… - Thorax, 2010 - thorax.bmj.com
Background Indacaterol is a long-acting inhaled β2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …
[HTML][HTML] Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
S Korn, E Kerwin, S Atis, C Amos, R Owen, C Lassen… - Respiratory …, 2011 - Elsevier
BACKGROUND: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for
the treatment of COPD. METHODS: This 12-week randomised, parallel-group study …
the treatment of COPD. METHODS: This 12-week randomised, parallel-group study …
[HTML][HTML] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack, S Piggott… - Respiratory …, 2010 - Springer
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
相关搜索
- efficacy of indacaterol β2 agonist
- efficacy of indacaterol subjects with copd
- subjects with copd β2 agonist
- safety of indacaterol patients with copd
- disease patients efficacy and safety
- efficacy of indacaterol 28 day
- 28 day β2 agonist
- asian areas efficacy and safety
- efficacy of indacaterol patients with copd
- patients with copd β2 agonist
- patients with copd effects of indacaterol